
Cerner Corporation CERN
Quarterly report 2022-Q1
added 12-16-2023
Cerner Corporation Cost of Revenue 2011-2026 | CERN
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Cerner Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 B | 933 M | 1.07 B | 937 M | 854 M | 779 M | 604 M | - | 515 M | 608 M | 442 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.07 B | 442 M | 774 M |
Quarterly Cost of Revenue Cerner Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 244 M | - | 251 M | 261 M | 231 M | - | 232 M | 212 M | 254 M | - | 272 M | 269 M | 253 M | - | 230 M | 239 M | 231 M | - | 203 M | 223 M | 199 M | - | 183 M | 206 M | 176 M | - | 191 M | 192 M | 169 M | - | 140 M | 162 M | 129 M | - | 120 M | 126 M | 127 M | - | 150 M | 148 M | 158 M | - | 120 M | 98.5 M | 90.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 272 M | 90.7 M | 191 M |
Cost of Revenue of other stocks in the Health information services industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Covetrus
CVET
|
3.72 B | - | - | $ 2.94 B | ||
|
Computer Programs and Systems
CPSI
|
176 M | - | 4.4 % | $ 133 M | ||
|
Accolade
ACCD
|
93.7 M | - | 0.29 % | $ 206 M | ||
|
iCAD
ICAD
|
2.97 M | - | - | $ 102 M | ||
|
Evolent Health
EVH
|
1.04 B | $ 3.94 | -1.5 % | $ 369 M | ||
|
Health Catalyst
HCAT
|
166 M | $ 2.29 | -4.39 % | $ 138 M | ||
|
HealthStream
HSTM
|
97.9 M | $ 22.91 | -0.69 % | $ 696 M | ||
|
Akerna Corp.
KERN
|
15.8 M | - | - | $ 161 M | ||
|
Premier
PINC
|
269 M | $ 28.26 | - | $ 2.33 B | ||
|
Progyny
PGNY
|
235 M | $ 25.87 | 0.74 % | $ 2.22 B | ||
|
HealthEquity
HQY
|
99.1 M | $ 91.73 | 0.13 % | $ 7.85 B | ||
|
So-Young International
SY
|
568 M | $ 2.7 | 5.47 % | $ 214 M | ||
|
American Well Corporation
AMWL
|
155 M | $ 4.85 | -1.22 % | $ 72.7 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
883 M | - | -10.39 % | $ 886 M | ||
|
Schrödinger
SDGR
|
75.5 M | $ 17.93 | 0.28 % | $ 1.3 B | ||
|
OptimizeRx Corporation
OPRX
|
28.6 M | $ 12.56 | 2.45 % | $ 215 M | ||
|
R1 RCM
RCM
|
1.16 B | - | - | $ 3.81 B | ||
|
GoodRx Holdings
GDRX
|
48.2 M | $ 2.75 | 1.29 % | $ 1.06 B | ||
|
Omnicell
OMCL
|
641 M | $ 44.75 | -1.21 % | $ 2.06 B | ||
|
1Life Healthcare
ONEM
|
319 M | - | - | $ 3.37 B | ||
|
Phreesia
PHR
|
61 M | $ 16.37 | -3.25 % | $ 893 M | ||
|
10x Genomics
TXG
|
209 M | $ 16.63 | 1.93 % | $ 1.95 B | ||
|
NantHealth
NH
|
28.8 M | - | -46.64 % | $ 10.4 M | ||
|
Zhongchao
ZCMD
|
6.95 M | $ 0.46 | 2.24 % | $ 2.39 M | ||
|
NextGen Healthcare
NXGN
|
275 M | - | - | $ 1.6 B | ||
|
Signify Health
SGFY
|
440 M | - | -0.02 % | $ 7.21 B | ||
|
Teladoc Health
TDOC
|
751 M | $ 7.07 | 1.0 % | $ 1.21 B | ||
|
Tabula Rasa HealthCare
TRHC
|
233 M | - | - | $ 255 M | ||
|
Veeva Systems
VEEV
|
677 M | $ 219.21 | -1.81 % | $ 35.2 B | ||
|
SCWorx Corp.
WORX
|
2.24 M | $ 0.21 | 12.22 % | $ 306 K |